Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2021

View Archived Issues

Modulating PPM1E is a therapeutic approach in type 2 diabetes

Genentech patents new TEAD inhibitors

E-Scape Bio discloses LRRK2 inhibitors

University of Kentucky identifies histone demethylase and Wnt signaling inhibitors

Janpix divulges new STAT5 inhibitors

Fochon Pharmaceuticals synthesizes new BTK inhibitors

Microbiome therapy SER-155 may restore colonization resistance and prevent infection

JSF-3151 demonstrates efficacy in mouse model of MRSA infection

Selecta and Takeda enter strategic licensing agreement for lysosomal storage disorders

OncoTherapy Science presents data on OTSA-101 in cervical cancer mouse model

Targeting ADGRF1 for obesity and associated metabolic diseases

Protein mimetic amyloid inhibitor shows antitumor activity in vivo

KRP-A218, an oral PI4KB inhibitor, is a potent antiviral in vivo

Taysha collaborates with UTSW on next-generation construct for the treatment of CLN7 disease

New model provides insight into tau propagation in early Alzheimer's disease

Depression's doldrums linked to diagnostic duality at ECNP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...